Copyright
©2014 Baishideng Publishing Group Inc.
World J Med Genet. May 27, 2014; 4(2): 19-26
Published online May 27, 2014. doi: 10.5496/wjmg.v4.i2.19
Published online May 27, 2014. doi: 10.5496/wjmg.v4.i2.19
Country | HBsAg positivity (%) | Ref. |
Southeast Asia | ||
Brunei | 4.7 | Sebastian et al[30] |
6.0 | Alexander et al[31] | |
Cambodia | 7.7 | OI et al[14] |
10.8 | Sa-Nguanmoo et al[10] | |
Indonesia | 3.5-9.1 | Hasan[11] |
4.9 | Achwan et al[12] | |
2.1-10.5 | Lusida et al[13] | |
Laos | 6.9 | Jutavijittum et al[24] |
8.7 | Sa-Nguanmoo et al[10] | |
Malaysia | 3.0-5.0 | Merican et al[22] |
0.5-1.8 | Yousuf et al[23] | |
Myanmar | 9.7 | Sa-Nguanmoo et al[10] |
Philippines | 10.0 | Lingao et al[17] |
2.0-16.0 | Lansang et al[18] | |
16.7 | Wong et al[19] | |
Singapore | 3.6-4.0 | James et al[28] |
2.7-4.0 | Ang et al[29] | |
Thailand | 4.0 | Suwannakarn et al[15] |
13.8 | Louisirirotchanakul et al[16] | |
Vietnam | 11.4 | Viet et al[20] |
7.5 | Reekie et al[21] | |
East Asia | ||
China | 2.4 | Ting-Lu et al[25] |
1.0 | Liu et al[26] | |
10.6 | Chen et al[27] | |
Japan | 0.8 | Merican et al[22] |
South Korea | 3.0-4.0, 6.0 | Kim et al[32] |
6.0 | Hyun et al[33] |
Lamivudine | Adefovir | Entecavir | Telbivudine | Tenofovir | Ref. | |
Analogue type | Nucleoside | Nucleotide | Nucleoside | Nucleoside | Nucleotide | |
Introduction (yr) | 1999 | 2002 | 2005 | 2006 | 2008 | |
Product name (company) | Zefix (GSK) | Hepsera (Gilead) | Baraclude (BMS) | Sebivo (Novartis) | Viread (Gilead) | |
Dose | 100 mg | 10 mg | 0.5 mg | 600 mg | 300 mg | |
Once daily | Once daily | Once daily | Once daily | Once daily | ||
Advantage | Low cost | Effective for HIV coinfection | Possible for pregnancy | Effective for HIV coinfection | [89] | |
Disadvantage | High rate of drug resistance | Renal dysfunction Fanconi anemia | Not recommend for pregnancy | Renal dysfunction | Renal dysfunction Fanconi anemia | |
Undetectable HBV-DNA | ||||||
HBeAg positive | 36% | 21% | 67% | 60% | 76% | [90] |
HBeAg negative | 89% | 72% | 90% | 88% | 93% | |
HBeAg seroconversion | 22% | 12% | 21% | 23% | 21% | [91] |
Drug-resistance | 24% | 0% | 0.2% | 4% | 0% | [92] |
Drug-resistant mutation | V173l, L180M, A181T, M204V/I | A181V/T, N236T | I169T, L180M, T184A/F/L/S, S202G/I, M204V, M250V | M204V/I | A181V/T, N236T |
- Citation: Utsumi T, Yano Y, Hotta H. Molecular epidemiology of hepatitis B virus in Asia. World J Med Genet 2014; 4(2): 19-26
- URL: https://www.wjgnet.com/2220-3184/full/v4/i2/19.htm
- DOI: https://dx.doi.org/10.5496/wjmg.v4.i2.19